Alessandro Broccoli
Overview
Explore the profile of Alessandro Broccoli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
1111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Grever M, Andritsos L, Anghelina M, Arons E, Banerji V, Barrientos J, et al.
Leukemia
. 2024 Jun;
38(7):1642-1644.
PMID: 38851853
No abstract available.
12.
Di Staso R, Casadei B, Gentilini M, Guadagnuolo S, Pellegrini C, Broccoli A, et al.
Ann Hematol
. 2024 May;
103(7):2499-2509.
PMID: 38695872
Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive large B-cell...
13.
Criscuolo M, Tosti M, Broccoli A, Varettoni M, Maraglino A, Anastasia A, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672557
Concern has emerged about the prevalence of second cancers among patients with hairy cell leukemia (HCL) treated with purine analogs. We investigated 513 patients with HCL treated with cladribine over...
14.
Broccoli A, Argnani L, Gugliotta G, Pellegrini C, Casadei B, Bagnato G, et al.
Oncologist
. 2024 Feb;
29(6):e789-e795.
PMID: 38339976
Introduction: Intensive treatment approaches are required for adult patients with Burkitt lymphoma (BL), although an univocal standard of care still does not exist. The use of frontline autologous stem cells...
15.
Bagnato G, Stefoni V, Broccoli A, Argnani L, Pellegrini C, Casadei B, et al.
Mediterr J Hematol Infect Dis
. 2024 Jan;
16(1):e2024004.
PMID: 38223480
We report the case of 2 patients with relapsed/refractory peripheral T-cell lymphoma treated with valemetostat tosylate, a selective dual inhibitor of histone-lysine N-methyltransferases enhancer of zest homolog 1 and 2,...
16.
Giladi O, Bagnato G, Gentilini M, Shimony S, Pasvolsky O, Berger T, et al.
Ann Hematol
. 2023 Nov;
103(3):803-811.
PMID: 37950052
The COVID-19 pandemic posed a major challenge in cancer care worldwide which might have an impact on the management of diffuse large B-cell lymphoma (DLBCL). We conducted a retrospective study...
17.
Zoli S, Pellegrini C, Casadei B, Broccoli A, Argnani L, Nanni L, et al.
Chemotherapy
. 2023 Nov;
69(1):23-26.
PMID: 37913761
Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), there are no uniform recommendations for second-line treatment in case of relapse. Case Presentation: Here, we present the case of...
18.
Peyronel F, Haroche J, Campochiaro C, Pegoraro F, Amoura Z, Tomelleri A, et al.
Blood
. 2023 Oct;
142(24):2119-2123.
PMID: 37871575
This geoepidemiological study, performed in Italy and France, shows that Erdheim-Chester disease is increasingly diagnosed and cases cluster in specific geographic areas, namely southern Italy and central France. Disease frequency...
19.
Broccoli A, Argnani L, Nanni L, Stefoni V, Pellegrini C, Casadei B, et al.
Blood Adv
. 2023 Sep;
7(21):6762-6766.
PMID: 37738174
No abstract available.
20.
Agostinelli C, Morandi L, Righi S, Cirillo L, Iommi M, Tonon C, et al.
Mod Pathol
. 2023 Sep;
36(12):100323.
PMID: 37678673
Primary diffuse large B-cell lymphoma of the primary central nervous system (CNS-DLBCL) is an aggressive disease, with dismal prognosis despite the use of high-dose methotrexate-based polychemotherapy. Our study aimed to...